State Physician Payment Disclosure Trends Is Your Company In Compliance or Is It Exposed to Potential Related Government Investigations? Susan Antonelli.

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

2 H.B. 4084, the Pharmaceutical Availability and Affordability Act, created the West Virginia Pharmaceutical Cost Management Council in W.Va. Code.
New Jersey Election Law Enforcement Commission Pay-to-Play January 2013.
VCOM Conflict of Interest Policy Overview of Financial Conflict of Interest Related to Research December 4, 2013.
Financial Conflict of Interest July 2012 rev
Executive Order #38 Issues & Guidance Fred M. LaMarca CPA, CFP® Zoltan Kemeny, CPA.
The Virginia Telephone Privacy Protection Act Virginia State Bar Annual Meeting Corporate Counsel Section CLE Program June 18, 2004.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Business-Related Hospitality and Entertainment Expenditures Guideline Changes Business-Related Hospitality and Entertainment Expenditures Guideline Changes.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
European Union of Medical Specialists November 18, 2011 Conference John McLoughlin Chairman, European Medical Technology Industry Association (EUCOMED)
Conflict of Interest (COI) Objectives: Provide an overview of financial conflict of interest (FCOI) related to research activities at Gillette Describe.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
2005 FPMP Compliance Training: Physician/Hospital Financial Arrangements Presented by: Brigid M. Maloney, Esq. Brigid M. Maloney, Esq. U.B. Associates.
1. 2 CVM’s OBJECTIVES u to stimulate the creation of savings and their investment in securities; u to promote the expansion and regular and efficient.
OFFICE OF INSURANCE REGULATION CURRENT STATE OF DISCOUNT MEDICAL PLAN ORGANIZATIONS (DMPOs) IN FLORIDA FLORIDA OFFICE OF INSURANCE REGULATION.
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
LOBBYING RULES IN MASSACHUSETTS: ARE YOU A LEGISLATIVE AGENT OR AN EXECUTIVE AGENT? Robert E. Cowden III Casner & Edwards, LLP 303 Congress Street Boston,
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
© 2012 Medical Mutual of Ohio Fees and Taxes in Healthcare Reform Patricia Decensi Vice President, Assistant General Counsel Medical Mutual of Ohio.
Introductory training Medical Technology Industry Code of Practice.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
VCU School of Medicine Policy on Industry Relations Effective July 1, 2009.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Presented by Gayle Garbolino-Mojica County Superintendent of Schools February 1, 2010 Reporting Gifts and Other Items Form 700.
California :: Delaware :: Florida :: New Jersey :: New York :: Pennsylvania :: Virginia :: Washington, D.C. :: 1 NEW OBLIGATIONS.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
New Staff Orientation: Industry Relations Emory School of Medicine Zainab R. Wurie, JD July 15, 2014.
State Ethics & Lobbying Laws for Pharmaceutical and Medical Device Companies John T. Bentivoglio (202) Steve Benz
1 Colorado Bar Association Health Law Section April 20, 2013 CMS Physician Payment Sunshine Act Final Rule: Sunshine or Black Hole? Michael M. Schmidt.
CONFLICTS OF INTEREST PRESENTED BY THE UMMC OFFICE OF INTEGRITY AND COMPLIANCE.
1 Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health PHC Meeting.
Ethical Guidelines and Prohibitions Arkansas School Laws Annotated Chapter 24.
ESB Copyright 2012 American Fidelity Assurance Company FCCMA June 1, 2012.
OPEN PAYMENTS UF College of Medicine Brown Bag July 23, 2013 Gary Wimsett, Jr., JD.
Understanding the Forces Driving Disclosure Preconference Session First Annual Summit on Sales & Marketing Disclosure for Drug, Device and Biotech Companies.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
HOSTING, ENTERTAINING AND PROVIDING GIFTS TO OFFICIALS: WHAT IS AND ISN’T ACCEPTABLE? ACI Conference, Moscow, March 2011.
© 2013 The McGraw-Hill Companies, Inc. All rights reserved. Ch 8 Privacy Law and HIPAA.
February 16, The Gift Ban Revolving Door Political Activities Ex Parte Communications.
+ Role of Industry in Clinical Care, Research, and Education.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
V IRGINIA A SSOCIATION OF S CHOOL B OARD O FFICIALS F ALL C ONFERENCE O FFICE OF THE S TATE I NSPECTOR G ENERAL 1.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
California’s New Compliance Law Kelly N. Reeves
Japan Fair Competition Code for Medical Devices Industry (JFCC-MDI)
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
Ethical Disclosures REGION 20 EDUCATION SERVICE CENTER [Wednesday, March 2, 2016]
Disclosure of Financial Interest Policy. Medical Staff Policy Approved by the MEC’s Aimed at protecting the integrity of the LMHS Medical Staffs Requires.
The IVD Australia Code of Conduct Edition 2.1
Utah Charter School Code & Rules
UCR PRO Reviewer Placemat
Analysis of the Proposed Sunshine Rule: Legal Considerations
Compliance Program 2018.
2018 Policy and Legislative Update February 18, 2018
California’s “Comprehensive Compliance Program” Law
Industry Induction Course
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Coalition Sample Code of Ethics
Presentation transcript:

State Physician Payment Disclosure Trends Is Your Company In Compliance or Is It Exposed to Potential Related Government Investigations? Susan Antonelli Morris, Esq. Manager, Compliance Program CSL Behring, LLC Pat Meehan, Esq. Patricia Hamill, Esq. Judson Aaron, Esq. Bob Rauker, Esq. Conrad OBrien PC © Copyright 2010 Conrad OBrien PC 1/17/20141

States with some form of potential Physician Payment Disclosure Laws Massachusetts 105 CMR § Vermont Act 59, Vt. Stat. tit. 18, Chapter 91 (§ ) California CAL. HSC. CODE § Maine Maine Rev. Stat. Title 22 Chapter 603 §2698-A Minnesota Minn. Stat. § Nevada NRS W. Virginia W. Va. Code §5A-3C-13 District of Columbia D.C. Code § Chapter 83, Title 17 D.C. Mun. Reg. New Jersey (outgoing AG recommendation ) 1/17/20142

State Comparison StateState Code of Conduct Compliance Program Requirement Disclosure Requirement Disclosure Public? Payments Restricted? Medical Device Incl? Physician Disclosure W. Virginia X California X PhRMA and self limits Maine X Nevada XX D.C. XX Vermont X Minnesota XXX Massachusetts XXXXXX New Jersey (rec) XXXX 1/17/2014 3

State Comparison Comments West Virginia: Pharma only required to disclose aggregate expenses associated with direct promotion and advertising of prescriptions to residents of W. VA. Information is confidential. No code of conduct, no medical device obligations, no physician disclosure Enforcement – no license to sell or distribute California: Requires a comprehensive compliance program which includes PhRMA Code on interactions with Health Care Professional (no medical device) Must have limits on gifts or incentives provided to medical or health professionals including annual dollar limit on gifts, promotional materials and other items. Exceptions include free samples intended for free distribution, financial support for CME, health educational scholarships and consulting fees at FMV for legitimate services Enforcement – no license to sell or distribute, misdemeanor possibly 1/17/20144

State Comparison Comments Maine: Pharma only required to disclose aggregate expenses associated with direct promotion and advertising of prescriptions to residents of Maine. All expenses associated with educational or informational programs All expenses associated with food, entertainment, gifts valued greater than $25, and anything provided to health care professional for less than market value All expenses associated with trips and travel All expenses associated with product samples, except those distributed by H C workers free of charge No code of conduct, no medical device obligations, no physician disclosure Exclusions include reasonable compensation for clinical trial and expenses associated with scholarship, educational, scientific and policy-making conference. $1,000 plus costs and attorneys fees. Civil violation 22 M.R.S.A. §47 has criminal provisions (up to 6 months and $10K fine) 1/17/20145

State Comparison Comments Nevada: Requires a device and drug company to adopt a marketing code of conduct that incorporates the principles of the Code on Interactions with Health Care Professional set forth by PhRMA or AdvaMed. Must adopt training program to provide regular training Conduct annual audits and have investigation policies and procedures Identify a compliance officer Enforcement – No license to sell or distribute 1/17/20146

State Comparison Comments District of Columbia: Pharma only required to disclose aggregate expenses associated with direct promotion and advertising of prescriptions to residents of DC. All expenses associated with educational or informational programs All expenses associated with food, entertainment, gifts valued greater than $25, and anything provided to health care professional for less than market value All expenses associated with trips and travel All expenses associated with product samples, except those distributed by H C workers free of charge DC Safe Rx law requiring training, code of conduct and education background Not included: reasonable compensation for clinical trial and expenses associated with scholarship, educational, scientific and policy-making conference. No medical device obligations, no physician disclosure Confidential $1,000 plus costs and attorneys fees. Civil violation. 1/17/20147

State Comparison Comments Vermont: No gifts except: Samples that are distributed for free to patients. The loan of a medical device for a short-term trial period, not to exceed 90 days, to permit evaluation of a medical device by a health care provider or patient. The provision of reasonable quantities of medical device demonstration or evaluation units to a health care provider to assess the appropriate use and function of the product and determine whether and when to use or recommend the product in the future. The provision, distribution, dissemination, or receipt of peer-reviewed academic, scientific, or clinical articles or journals and other items that serve a genuine educational function provided to a health care provider for the benefit of patients. Scholarship or other support for medical students, residents, and fellows to attend a significant educational, scientific, or policy-making conference or seminar of a national, regional, or specialty medical or other professional association if the recipient of the scholarship or other support is selected by the association. Rebates and discounts for prescribed products provided in the normal course of business. Labels approved by the federal Food and Drug Administration for prescribed products. 1/17/20148

State Comparison Comments Vermont (Continued) Disclosure of allowable gifts, except Royalties, licensing fees, rebates, discounts, payments for clinical trial Public – but strong trade secret law that might prevent disclosure Enforcement: The Attorney General of Vermont may bring an action for injunctive relief, costs, and attorney's fees and may impose on a manufacturer that violates this section a civil penalty of no more than $10,000 per violation. Each unlawful gift shall constitute a separate violation. Criminal penalties possible under 18 V.S.A. § 131. Criminal penalty 1/17/20149

State Comparison Comments Minnesota: Drug distributors (not medical device)cannot offer any gift of value to a practitioner Exceptions: Samples that will be distributed to patients for free Items with a total combined retail value (calendar year) of not more than $50 Payment for medical conference, professional meeting or educational program – not made directly to practitioner Reasonable honoraria and payment of expenses for serving as faculty member at a medical conference or professional meeting. Compensation for consulting services for genuine research project Publications and educational materials & Salaries or other benefits to employees Annual report itemizing the nature and value of any payments exceeding $100 in value Public Disclosure Civil penalty not exceeding $10,000 for each separate violation. Minn. Rev. Stat. § /17/201410

State Comparison Comments Massachusetts Marketing code of conduct by July 1, 2009– PhRMA and AdvaMed (floor) Prohibited Activities: Grants, scholarships, subsidies, consulting contracts, or educational items in exchange for prescribing or disbursing prescription drugs or medical devices. Entertainment or recreational items of any value; Payments in cash or cash equivalents either directly or indirectly except as compensation for bona fide services; The provision of complimentary items such as pens, coffee mugs, gift cards, flowers, etc. Meals that are part of an entertainment or recreational event. Meals that are offered without an informational presentation made by a pharmaceutical or medical device marketing agent or without such agent being present. Meals outside of a HCPs office, hospital, academic medical center or specialized training facility; Meals provided to a HCPs spouse or other guest Support for the cost of travel, lodging, attendance or other personal expenses of non-faculty HCPs Direct payment of meals Sponsorship of CME that is not compliant with the appropriate standards set by ACCME or other equivalent accrediting body. 1/17/201411

State Comparison Comments Massachusetts (continued) Permissible Activities (examples): reasonable consulting fees for bona fide services, training, advisory boards, licensing and royalties Starting July 1, 2010 disclosure of fee or other item of value exceeding $50.00 Public Disclosure Enforcement: $5,000 for each transaction, occurrence or event 1/17/201412

State Comparison Comments New Jersey (recommendation by outgoing AG): Includes drug and device companies Ban essentially all gifts except items that provide a direct benefit to patients such as free samples or reimbursement for service at a CME No meals except modest ones at CME seminars, third-party conferences and professional meetings Physician disclosure of more than $200 over preceding 2 years. Public disclosure of the physician disclosures Public database of manufacturer (medical device and drug) disclosures (low threshold such as $25-100) Restrictions on CME funding and ability to influence Restrictions on opting-out of prescriber identified data No code of conduct mentioned 1/17/201413

PhRMA, AdvaMed and MDMA Codes of Conduct Pharmaceutical Research and Manufacturers of America (PhRMA) Code of Conduct Advanced Medical Technology Association (AdvaMed) The Medical Device Manufacturers Association (MDMA) 1/17/201414

Proposed Federal Sunshine Act House Bill (D-Hill) H.R and Americas Affordable Health Choice Act of 2009 Senate Bill (R-Grassley, D-Kohl) S. 301 and Chairmans Mark Submitted as part of Health Care Reform 1/17/201415

Comments/Comparison Proposed Federal Sunshine Act* ProvisionHouseSenate Pre-emptionSame as SenateLatest version states it will preempt except any law or regulation of a State or of a political subdivision of a State that requires the disclosure or reporting of information not required to be disclosed or reported Start Date for reporting January 1, 2010January 1, 2012 First ReportMarch 31, 2011March 31, 2013 Excluded Items (examples) Any payments under $5; The loan of a device for evaluation purposes for less than 90 days ; samples given away to patients for free A transfer of value of less than $10, unless the aggregate amount during the calendar year exceeds $100. ConsultingMust be disclosedSame as House PenaltiesSame as Senate except knowingly aggregate penalty is the greater of $1,000,000 or 0.1 times revenues. A civil penalty of not less than $1,000, but not more than $10,000,for each payment not reported with a cap of $150,000. Knowingly failing to submit payment can result in a penalty of not less than $10,000, but not more than $100,000, for each payment. Penalty will not exceed $1m PublicYes 1/17/201416

Comments/Comparison Proposed Federal Sunshine Act (continued)* ProvisionHouseSenate Payments to: Physician/Physician practice group Any other prescriber Pharmacy/pharmacist Health insurance issuer, group health plan, other entity offering a health benefits plan PBM, Hospital, Medical school, GPO CME sponsor Patient advocacy/disease specific group Organization of health care professionals Biomedical researcher Physician Physician medical practice Physician practice group Hospital with an approved medical residency training program Physician Ownership Ownership or investment interest in manufacturer (other than publicly traded security and mutual fund) held by a physician or immediate family member * Not a complete comparison Just specific examples 17

Disclosure Trends Greater transparency = Greater Reporting Larger fines = More Investigations More Information = More Govt Entities More Paperwork = More Mistakes Broader scope = Device and Diagnostic* * Minnesota Legislator proposes broadening gift ban to device companies 1/17/201418

Things to Consider Educate sales and marketing force now Do not forget to include others generating consulting and development agreement Develop valuation plan for non-cash payments Implement most stringent policies now? Plan for mistakes in reporting now Expect reporting issues between state requirements and IRS Combined Device and Drug companies 1/17/201419

Questions THANK YOU 1/17/201420